Palisade Bio, a biopharmaceutical company focused on gastrointestinal complications, has announced the completion of patient enrollment in its LB1148 dose optimization study. The study aims to generate valuable data on pharmacokinetics and pharmacodynamics across multiple doses in healthy adult volunteers.
This milestone brings Palisade Bio closer to obtaining Phase 2 topline data for the prevention of post-surgical abdominal adhesions. The results from these studies will inform future clinical development of LB1148.
LB1148 is a broad-spectrum serine protease inhibitor developed by Palisade Bio that neutralizes digestive enzymes and potentially reduces intestinal damage. Previous clinical studies have shown positive outcomes in reducing the severity and incidence of post-surgical abdominal adhesions, as well as speeding up the return of bowel function after surgery.
The current U.S. Phase 2 study is evaluating LB1148's effectiveness in reducing intra-abdominal adhesions, accelerating gastrointestinal function recovery, and preventing post-operative ileus in subjects undergoing elective bowel resection.